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Cost-effectiveness of open versus endovascular repair
of abdominal aortic aneurysm in the OVER trial
Kevin T. Stroupe, PhD,a Frank A. Lederle, MD,b Jon S. Matsumura, MD,c Tassos C. Kyriakides, PhD,d
Yvonne C. Jonk, PhD,b Ling Ge, MS,a and Julie A. Freischlag, MD,e for the Open Versus Endovascular
Repair (OVER) Veterans Affairs Cooperative Study Group,* Hines, Ill; Minneapolis, Minn; Madison, Wisc;
West Haven, Conn; and Baltimore, Md
Objective: This study was conducted to determine the costs and comparative cost-effectiveness of two methods of
abdominal aortic aneurysm (AAA) repair in the Open Versus Endovascular Repair (OVER) Veterans Affairs (VA)
Cooperative Study, a multicenter randomized trial of 881 patients.
Methods: The primary outcomes of this analysis were mean total health care cost per life-year and per quality-adjusted
life-year (QALY) from randomization to 2 years after. QALYs were calculated from EuroQol (EQ)-5D questionnaires
collected at baseline and annually. Health care utilization data were obtained directly from patients and from national VA
and Medicare data sources. VA costs were obtained from national VA sources using methods previously developed by the
VA Health Economics Resource Center. Costs for non-VA care were determined from Medicare claims data or billing
data from the patient’s health care providers.
Results: After 2 years of follow-up, mean life-years were 1.78 in the endovascular repair group and 1.74 in the open repair
group (difference, 0.04; 95% confidence interval [CI], 0.03 to 0.09; P  .29). Mean QALYs were 1.462 in the
endovascular group and 1.461 in the open group (difference adjusting for baseline EQ-5D score, 0.006; 95% CI,0.038
to 0.052; P  .78). Mean graft costs were higher in the endovascular group ($14,052 vs $1363; P < .001), but length
of stay was shorter (5.0 vs 10.5 days; P < .001), resulting in a lower mean cost of the hospital admission for the AAA
procedure in the endovascular repair group of $37,068 vs $42,970 (difference, –$5901; 95% CI, –$12,135 to –$821;
P .04). After 2 years, total health care costs remained lower in the endovascular group, but the difference was no longer
significant (–$5019; 95% CI, –$16,720 to $4928; P  .35). The probability of endovascular repair being less costly and
more effective was 70.9% for life-years and 51.4% for QALYs.
Conclusions: In this multicenter randomized trial, endovascular AAA repair resulted in lower cost and better survival than
open repair after the initial hospitalization for repair; but after 2 years, survival, quality of life, and costs were not
significantly different between the two treatments. ( J Vasc Surg 2012;56:901-10.)
g
t
A
o
l
d
c
e
c
E
p
y
2
e
A
M
o
bForty thousand elective procedures are performed in
the United States each year to repair abdominal aortic
aneurysm (AAA), resulting in 1250 perioperative
deaths.1 The introduction of endovascular repair in the
1990s as a less invasive alternative to open repair therefore
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http://dx.doi.org/10.1016/j.jvs.2012.01.086enerated considerable interest,2 and several randomized
rials were undertaken to compare the two procedures.
lthough these trials have generally reported reduced peri-
perative mortality with endovascular repair, midterm and
ong-term outcomes have been similar for the two proce-
ures.3-5 This similarity increases the need for an accurate
omparison of costs, particularly in view of the high cost of
ndovascular grafts, which has led most previous authors to
onclude that endovascular repair is not cost-effective.3,6,7
The Department of Veterans Affairs (VA) Open Versus
ndovascular Repair (OVER) trial recently reported a com-
arison of clinical outcomes of the two procedures at 2
ears after randomization.5 We report here, for the same
-year period, total health care costs and comparative cost-
ffectiveness of elective open and endovascular repair of
AA in the VA OVER trial.
ETHODS
Patients and clinical outcomes. The general meth-
ds and 2-year clinical outcomes of the OVER trial have
een reported previously.5 Briefly, 881 patients were ran-
omized between October 2002 and April 2008 at 42 VA
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October 2012902 Stroupe et almedical centers: 444 to endovascular repair and 437 to
open repair. Eligible patients had AAAwith (1) a maximum
external diameter of 5.0 cm, (2) an associated iliac aneu-
rysm with a maximum diameter of 3.0 cm, or (3) a
maximum diameter of 4.5 cm plus rapid enlargement or
saccular morphology. Patients also had to be candidates for
both procedures and were excluded if they had undergone
previous abdominal aortic surgery, needed urgent repair, or
were unable or unwilling to give informed consent or
follow the protocol.
Follow-up visits were scheduled 1 month after aneu-
rysm repair, 6 and 12 months after enrollment, and then
yearly. Patients were called monthly during the first 14
months after repair and then annually midway between
study visits to identify outcomes and were asked to log all
health care visits. All follow-up visits after endovascular
repair included a computed tomography scan and plain
radiography of the abdomen; after open repair, only a
computed tomography scan at 1 year was specified, a dif-
ference intended to reflect usual clinical practice.
The trial was designed to have 80% power to detect a
25% relative reduction in death after 9 years.5 No additional
power calculations were conducted for the cost analysis, for
which the primary outcome was mean total health care cost
per life-year and per quality-adjusted life-year (QALY). As
described in the previous report,5 the protocol originally
specified publication of 1-year results when available on all
patients, amended to include follow-up data to 2 years after
randomization as of October 15, 2008. Mean follow-up
was 1.8 years, and 80% of patients had completed 2 years of
follow-up or had died 2 years. Perioperative mortality (30
days or inpatient) was lower for endovascular repair (0.5% vs
3.0%; P  .004), but the difference in mortality at 2 years
(7.0% vs 9.8%) was not statistically significant (P  .13), nor
was the difference between the two groups in major morbid-
ity, procedure failure, secondary therapeutic procedures,
aneurysm-related hospitalizations, or health-related quality of
life (QOL).5
Assessment of utilization and costs. The clinical trial
database of OVER patients was linked to national VA and
Medicare databases to obtain information on health care
utilization and cost. All health care costs were included and
were adjusted to 2008 U.S. dollars with the Consumer Price
Index. Costs are estimated from the perspective of all health
care providers (ie, the VA and private-sector providers).
To obtain the level of detail needed for comparison,
costs for the hospitalizations during which the AAA repair
operation was performed were obtained from the VA De-
cision Support System (DSS) National Data Extracts.8 The
DSS extracts information from VA accounting and payroll
system and combines this with workload information from
patient care and administrative departments to produce
estimates of cost. Costs are compiled from intermediate
products that make up the encounter, such as a radiologic
test, a day in a ward, or a 15-minute block of time in an
operating room. A hospital stay is divided into segments
according to the bed section, such as medical care, a surgi-
cal ward, or a unit providing long-term care. TWithin each bed section, DSS allocates costs among six
utually exclusive categories: surgery, nursing, laboratory,
adiology, pharmacy, and other. The “surgery” cost cate-
ory could thus be included whether or not a patient is on
he surgery bed section and encompasses preoperative care,
he operating suite, and the recovery room on the day of
urgery. “Nursing” includes the operating costs of regular
cute-care wards and long-term care units, excluding phy-
ician costs. The category “other” includes daily physician
osts, ward clerks, respiratory therapy, dietetics, and social
ork, among others. Each of these six categories includes
xed direct costs that are directly attributable to that cate-
ory but incurred regardless of the volume of services
rovided and fixed indirect costs, including overhead de-
artments such as housekeeping, engineering, and admin-
stration, allocated by formulas derived from intermediate
roduct use.
Graft components used for each patient were recorded
n OVER study forms, and prices were obtained from the
A National Patient Prosthetics Database. If the price for a
pecific component was not available, we used the price of a
omponent in the same class from the same manufacturer.
osts relating to the first procedure at which the AAA
epair was completed were compared. Prior aborted proce-
ures and subsequent procedures occurring during other
ospitalizations were included in overall costs but not in
he AAA repair hospitalization cost.
All other VA utilization data, including other hospital
tays, outpatient visits, contract care, and outpatient med-
cations acquired from VA, were obtained from the VA
edical SAS Inpatient and Outpatient Data sets extracted
rom the National Patient Care Database, which captures
ll utilization from the electronic record system of local VA
edical centers,9,10 and also from the Fee Basis files, which
eport care provided to VA patients by contract providers
utside of VA facilities.11
The costs for VA utilization other than the hospitaliza-
ion for the AAA procedure were obtained from the VA
ealth Economics Resource Center (HERC) average cost
ata sets.12-14 The average cost data sets are more directly
omparable to the costing used for non-VA health care
tilization at Medicare-financed facilities than the DSS
ethod used for the AAA repair hospitalization. In the
ERC average cost data sets, the costs of acutemedical and
urgical hospital care are obtained using an econometric
ost function that was developed by modeling costs from
edicare claims data as a function of Diagnosis Related
roup weights, length of stay, and demographic and other
linical information.
The Medicare costs used in this cost function were
erived from charges in the Medicare claims data and
djusted to costs using cost-to-charge ratios from cost
eports that facilities submit to the Center forMedicare and
edicaid Services.12 The resulting cost function provides
n estimate of the relationship between inpatient costs and
haracteristics of the patient and admission such as age, sex,
iagnosis Related Group weights, and length of stay.
hese relationships are then applied to information in the
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medical and surgical costs.
Costs for nonacute hospital stays (eg, rehabilitation,
mental health, and long-term care) were estimated by
calculating an average cost per day for each type of care
from the DSS National Data Extracts and then multiplying
by length of stay. Costs for VA outpatient visits were based
on reimbursement rates of Medicare and other health care
payers. Costs for prescriptions obtained from the VA were
based on the VA’s acquisition and dispensing costs from the
VA DSS National Data Extracts Pharmacy data sets.15
Non-VA health care utilization was obtained from
Medicare claims data (available for 67% of the patient-
months in the study period) and from patient self-reported
data verified with billing data from the facilities where care
was received. Costs were estimated by multiplying the
health care charges in theMedicare claims or billing data by
the hospital-specific cost-to-charge ratios obtained from
cost reports submitted to Medicare annually.16 For the
self-reported inpatient admissions or nursing home stays
for which we did not have corresponding billing informa-
tion, we estimated costs based on the self-reported length
of stay and the available billing information. We calculated
a cost per day from the available billing data and then
multiplied the cost per day by the self-reported length of
stay to estimate a cost for that health care encounter.
Assessment of effectiveness. Effectiveness was mea-
sured in life-years after randomization and in QALYs,
which incorporate health-related QOL and medical out-
comes into a single measure.16 Health-related QOL was
assessed using the EQ-5D (EuroQol, Rotterdam, The
Netherlands), a brief questionnaire designed for this pur-
pose. To compute QALYs, EQ-5D index scores obtained
at baseline, 6 months, and annually were converted into
utility weights based on U.S. population preferences.17
These utility weights range from 0.11 for the worst
EQ-5D index score to 1.0 for the best on a scale where
0.0  death and 1.0  perfect health. When values were
missing, the most recent score was used. The utility weights
were connected with straight lines (and connected to 0.0
for the date of death) to construct the quality-adjusted
survival curve. QALYs were computed from the area under
the curve, calculated using the trapezoid rule.
Analysis. We compared cost and effectiveness (mea-
sured in life-years and QALYs) between patients random-
ized to endovascular and open repair on an intention-to-
treat basis, regardless of the occurrence or type of the actual
AAA repair. We calculated 95% confidence intervals (CIs)
around differences in mean utilization and costs between
patients randomized to endovascular or open repairs using
bias-corrected accelerated bootstrapping to adjust for
skewing in the data.18 Means were used, as recommended
by guidelines,19 because total costs for the patient group
can be derived from them to estimate budgets. Medians are
also shown. P values were estimated from the bootstrap-
ping procedure and t tests. Because of multiple compari-
sons, marginal values should be interpreted with caution.
We estimated QALYs at 2 years after randomization and palculated the 95% CI around the difference in mean
ALYs using the bootstrap method. The difference in
ean QALYs was adjusted for baseline EQ-5D utility
cores using regression methods.20 P values for life-years
ere obtained from t tests, and P values for QALYs were
btained from the regression analysis. As is standard in
ost-effectiveness analyses, we discounted costs, life-years,
ndQALYs at 3% per year starting with the date of random-
zation.16
To assess the precision of our cost-effectiveness anal-
sis, we used bootstrap methods to examine the distri-
ution of the incremental cost (ie, mean total costs of the
ndovascular group minus mean total costs of the open
epair group) and incremental effectiveness (ie, mean
ife-years or QALYs for the endovascular group minus
ean life-years or QALYs for the open repair group)
cross regions of the cost-effectiveness plane.7,21 This
ethod provides a means for quantifying the robustness
f the cost-effectiveness analysis results across the four
uadrants of the cost-effectiveness plane showing the
elationship between differences in mean costs and mean
ffectiveness.
As a sensitivity analysis, we estimated costs using
aplan-Meier sample average estimators, which account for
ensoring in estimating mean total health care costs.22 The
ethod involves dividing the study period into smaller time
ntervals, estimating the average costs over each interval for
atients alive at the start of the interval, multiplying the
verage total cost in each interval by the Kaplan-Meier
urvival probability of being alive at the beginning of the
nterval, and calculating the mean total costs by summing
hese costs over the study period.
ESULTS
The mean cost of the hospital admission for the AAA
rocedure was lower for the endovascular repair group
$37,068) than for the open repair group ($42,970), for a
ifference of –$5901 (95% CI, –$12,135 to –$821; P 
04; Table I). The surgical procedure cost substantially
ore in the endovascular group ($23,618 vs $11,594; P
001) because of the much higher costs of the grafts
$14,052 vs $1363; P  .001). However, patients in the
ndovascular group were hospitalized for less than half the
umber of days (mean, 5.0 vs 10.5 days; P  .001; Table
I) and had shorter intensive care unit stays (mean, 1.9 vs
.6 days; P  .001) during that admission. As a conse-
uence, other components of the hospitalization for the
AA procedure were more costly for the open group,
ncluding nursing, pharmacy, and laboratory costs, which is
lso reflected in the fixed direct and indirect costs for these
ost categories (as shown for nursing in Table I).
Compared with the open group, the endovascular
roup had significantly more VA outpatient visits in the 30
ays after the admission for the AAA procedure (Table II)
nd significantly higher costs related to VA outpatient visits
n the 30 days after the AAA repair admission and from 30
ays to 1 year, but differences in overall costs during these
eriods were not significant (Table III). Apart from the
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were similar between the two groups. By 2 years after
randomization, mean total costs were $75,325 in the en-
dovascular group and $80,344 in the open group, a non-
significant difference of –$5019 (95% CI, –$16,720 to
$4928; P  .35). Cost results from the Kaplan-Meier
sample average sensitivity analysis were similar to the cost
results reported in the Tables at 2 years of $77,161 vs
$82,290 (difference, –$5129).
Cost-effectiveness analysis. After 2 years of follow-
up, mean life-years were 1.78 for the endovascular group
and 1.74 for the open group (difference, 0.04; 95% CI,
0.03 to 0.09; P  .29). Health-related QOL, as mea-
sured by the EQ-5D, did not differ significantly between
the two groups at baseline, 6 months, 1 year, or 2 years
(Table IV). When this QOL information was combined with
life years, the endovascular group had a mean of 1.462
QALYs, whereas the open group had 1.461 QALYs (differ-
ence adjusting for baseline EQ-5D score, 0.006; 95% CI,
0.038 to 0.052; P  .78). With lower costs and more
life-years, endovascular repair was the dominant strategy and
so we did not calculate an incremental cost-effectiveness ratio
(ie, the cost per life-year saved).
The bootstrap analysis to characterize the precision of
our cost-effectiveness estimates, conducted by 2000 sam-
plings (with replacement) of the 881 observations from
trial participants, is plotted in the Fig. When effectiveness
was measured in life-years, the bootstrap analyses indicated
that there was a 70.9% probability of endovascular repair
being less costly and more effective than open repair (Fig,
Table I. Costs of hospitalization for abdominal aortic ane
Itema
Endovascular repair
(n  444)
Surgery bed section 35,695 (24,762) 40
Nursing cost category 6193 (11,328) 16
Intensive care units 2349 (5639)
Wards 830 (1646)
Otherb 412 (1069)
Fixed indirect total 2482 (4489)
Fixed direct total 119 (271)
Surgery cost category 23,618 (8453) 11
Operating room 3219 (2857)
Surgical implants 14,052 (3626)
Anesthesia 1184 (1180)
Other 447 (1974)
Fixed indirect total 4389 (4108)
Fixed direct total 327 (351)
Radiology cost category 1597 (3071)
Laboratory cost category 796 (1473)
Pharmacy cost category 895 (1914)
Other cost category 2597 (4911)
Other bed sections 1373 (8752)
Total cost 37,068 (28,551) 42
Total cost, median (IQR) 32,094 (26,306, 40,038) 30
CI, Confidence interval; IQR, intererquartile range.
aCosts are in U.S. dollars and are shown as mean (standard deviation) excep
bRecovery room, stepdown, etc.A). When effectiveness was measured in QALYs, the prob- $bility that endovascular repair was less costly and more
ffective dropped to 51.4% (Fig, B). The proportions of
bservations from the bootstrap analyses below the diago-
al lines indicate the observations that would favor endo-
ascular repair if the decision maker were willing to pay
50,000 or $100,000 per life-year or QALY. From these
bservations, if willing to pay $50,000, endovascular repair
s preferred in 88.1% of observations using life-years and in
3.4% using QALYs, whereas if willing to pay $100,000,
he proportions are 90.4% and 83.3%, respectively.
ISCUSSION
In this multicenter randomized trial, survival, QOL,
nd costs after 2 years were not significantly different
etween endovascular and open repair of AAA. The hospi-
al admission for AAA repair was less expensive in the
ndovascular repair group, largely because of shorter hos-
ital and intensive care length of stay, and despite the high
ost of the endovascular grafts. Two-year costs apart from
he hospital admission for the AAA procedure were nearly
dentical between the two groups.
Most previous studies have found endovascular repair
o be a more expensive strategy despite the shorter hospital
nd intensive care length of stay.3,6,7 Randomized trials are
onsidered one of the most informative approaches to
conomic evaluation,23 and two European randomized
rials of open vs endovascular AAA repair have published
ost data. In the United Kingdom Endovascular Aneurysm
epair Trial 1 (EVAR 1), there was a trend toward higher
ost with endovascular than open repair ($19,698 vs
repair
pen repair
(n  437)
Cost difference
(95% CI) P
(48,519) 4474 (10,265 to 67) .04
(24,025) 9815 (12,857 to 7833) .001
(11,803) 4118 (5757 to 3089) .001
(2411) 486 (766 to 233) .0005
(3717) 862 (1372 to 575) .001
(11,219) 4097 (5615 to 3206) .001
(1358) 252 (444 to 156) .0002
(8813) 12,024 (10,85213,187) .001
(3295) 683 (1070 to 280) .001
(2935) 12,689 (12,22713,099) .001
(1586) 344 (526 to 158) .0003
(1545) 32 (181 to 286) .79
(3354) 407 (105 to 907) .11
(459) 77 (129 to 22) .005
(2382) 343 (0 to 717) .06
(3169) 1238 (1612 to 958) .001
(8946) 1838 (3446 to 1291) .001
(11,098) 3951 (5254 to 3003) .001
(11,599) 1429 (2804 to 50) .04
(51,952) 5901 (12,135 to 821) .04
(21,785, 42,768)
n median is specified. See the Methods section for explanation of items.urysm
O
,169
,007
6466
1317
1274
6579
371
,594
3902
1363
1528
415
3982
405
1253
2034
2733
6548
2802
,970
,50617,917) that became statistically significant when late
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Variablea
Endovascular repair
(n  444)
Open repair
(n  437) Difference (95% CI) P
Before AAA repair (per randomized patient)
VA utilization
Acute inpatient days 0.27 (1.52) 0.29 (1.3) 0.02 (0.16 to 0.26) .87
Admissions, No. 0.10 (0.36) 0.13 (0.45) 0.02 (0.08 to 0.03) .42
Rehabilitation, mental health, and long-term care days 0.018 (0.27) 0 (0) 0.018 (0 to 0.064) .16
Admissions, No. 0.0045 (0.067) 0.0020 (0.05) 0.002 (0.006 to 0.009) .57
Outpatient visits 2.35 (5.0) 2.54 (4.93) 0.18 (0.77 to 0.55) .58
Outpatient prescriptionsb 3.91 (7.46) 5.42 (13.14) 1.51 (3.09 to 0.32) .04
Non-VA utilization
Acute inpatient days 0.08 (1.31) 0.09 (1.87) 0.01 (0.34 to 0.14) .91
Nursing home days 0 (0) 0.02 (0.43) 0.02 (0.1 to 0) .32
Outpatient visits 0.11 (0.6) 0.07 (0.46) 0.033 (0.03 to 0.11) .37
Admission for AAA repair 1 year of randomization
Patients, No. 440 429
Days per admission 5.0 (8.9) 10.5 (12.2) 5.5 (6.9 to 4.1) .001
Discharge after AAA repair to 30 days (per randomized
patient)
VA utilization
Acute inpatient days 0.44 (1.98) 0.62 (2.76) 0.18 (0.54 to 0.1) .27
Admissions, No. 0.09 (0.31) 0.11 (0.36) 0.015 (0.06 to 0.03) .5
Rehabilitation, mental health, and long-term care days 0.08 (0.86) 0.46 (3.13) 0.38 (0.75 to 0.13) .02
Admissions, No. 0.01 (0.13) 0.03 (0.21) 0.02 (0.04 to 0.002) .08
Outpatient visits 2.71 (2.0) 2.01 (1.8) 0.7 (0.44 to 0.94) .001
Outpatient prescriptionsa 4.95 (5.4) 4.43 (5.97) 0.52 (0.22 to 1.27) .18
Non-VA utilization
Acute inpatient days 0.06 (0.61) 0.14 (1.1) 0.08 (0.24 to 0.02) .17
Nursing home days 0.17 (1.79) 0.30 (2.22) 0.12 (0.38 to 0.15) .36
Outpatient visits 0.13 (0.52) 0.10 (0.52) 0.03 (0.05 to 0.09) .47
30 days to 1 year (per randomized patient)
VA utilization
Acute inpatient days 2.50 (9.2) 2.04 (8.95) 0.43 (0.78 to 1.67) .49
Admissions, No. 0.46 (0.9) 0.29 (0.73) 0.17 (0.06 to 0.27) .003
Rehabilitation, mental health, and long-term care days 2.6 (21.2) 2.22 (14.9) 0.38 (1.76 to 3.23) .76
Admissions, No. 0.05 (0.29) 0.03 (0.21) 0.022 (0.01 to 0.06) .2
Outpatient visits 19.6 (12.7) 18.0 (15.6) 1.57 (0.35 to 3.37) .1
Outpatient prescriptionsa 59.9 (40.1) 59.4 (45.5) 0.58 (5.1 to 6.18) .84
Non-VA utilization
Acute inpatient days 0.84 (3.83) 1.74 (12.1) 0.9 (2.36 to 0.03) .14
Nursing home days 1.18 (9.66) 1.61 (10.2) 0.42 (1.73 to 1) .53
Outpatient visits 1.83 (5.53) 2.41 (6.72) 0.58 (1.45 to 0.24) .16
AAA repair from 1 to 2 years
Patients, No. 3 ... ...
Days per admission 27.7 (36.1) ... ...
1 to 2 years (per randomized patient)
VA utilization
Acute inpatient days 1.44 (4.57) 2.04 (8.16) 0.6 (1.6 to 0.2) .18
Admissions, No. 0.33 (0.8) 0.35 (0.88) 0.02 (0.14 to 0.09) .77
Rehabilitation, mental health, and long-term care days 0.89 (15.1) 2.74 (21.4) 1.85 (4.47 to 0.46) .14
Admissions, No. 0.009 (0.15) 0.050 (0.25) 0.04 (0.07 to 0.02) .003
Outpatient visits 16.0 (14.5) 15.8 (16.5) 0.19 (1.97 to 2.19) .86
Outpatient prescriptionsa 60.3 (48.7) 63.7 (55.9) 3.38 (10.8 to 3.31) .34
Non-VA utilization
Acute inpatient days 1.23 (5.4) 2.23 (19.2) 1 (3.6 to 0.36) .3
Nursing home days 1.76 (11.57) 0.89 (7.45) 0.87 (0.16 to 2.49) .19
Outpatient visits 2.49 (7.9) 2.35 (5.93) 0.13 (0.69 to 1.1) .78
AAA, Abdominal aortic aneurysm; VA, Department of Veterans Affairs.
aMean (standard deviation) values are given.
bA prescription is a 30-day supply.
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Variablea
Endovascular repair
(n  444)
Open repair
(n  437)
Cost difference
(95% CI) P
Before AAA repair
VA costs
Acute inpatient care 925 (4654) 935 (5379) 11 (703 to 635) .98
Rehabilitation, mental health, and
long-term care 10 (155) 0 (0) 10 (0 to 34) .16
Outpatient visits 980 (1974) 978 (2290) 2 (308 to 248) .99
Outpatient pharmacy 100 (292) 102 (205) 2 (31 to 36) .93
Non-VA costs
Acute inpatient care 227 (3774) 15 (304) 212 (131034) .01
Nursing home 0 (0) 1 (25) 1 (8 to 0) .32
Outpatient visits 29 (280) 26 (420) 3 (61 to 38) .90
Other care 20 (322) 8 (110) 13 (6 to 69) .43
Total 2292 (7261) 2064 (6823) 227 (646 to 1198) .63
Median (IQR) 576 (102, 1425) 582 (89, 1317)
AAA repair in year 1
Total, per randomized patient 37,068 (28,551) 42,338 (51,475) 5269 (11,591 to 518) .03
Median (IQR) 32,094 (26,306, 40,038) 30,077 (21,684, 42,694)
Discharge after AAA repair to 30 days
VA costs
Acute inpatient care 1012 (4528) 1447 (7145) 435 (1332 to 247) .28
Rehabilitation, mental health, and
long-term care 67 (703) 344 (2854) 277 (618 to 62) .05
Outpatient visits 960 (1361) 361 (625) 599 (481-774) .001
Outpatient pharmacy 106 (202) 96 (195) 10 (18 to 35) .47
Non-VA costs
Acute inpatient care 56 (516) 322 (2233) 266 (543 to 91) .02
Nursing home 48 (533) 59 (465) 12 (70 to 66) .73
Outpatient visits 34 (215) 19 (139) 15 (5 to 46) .23
Other care 61 (453) 50 (321) 11 (35 to 71) .67
Total 2344 (4834) 2700 (8305) 355 (1272 to 554) .44
Median (IQR) 1085 (337, 2115) 409 (132, 1051)
30 days to 1 year
VA costs
Acute inpatient care 6284 (23,209) 4609 (19,013) 1675 (946 to 4588) .24
Rehabilitation, mental health, and
long-term care 1239 (9478) 1544 (14,841) 304 (2312 to 1088) .72
Outpatient visits 6810 (5240) 4862 (4918) 1948 (1279-2605) .001
Outpatient pharmacy 1212 (1581) 1266 (3845) 55 (748 to 197) .78
Non-VA costs
Acute inpatient care 1637 (7695) 2478 (10,846) 841 (2222 to 340) .19
Nursing home 337 (3179) 528 (3805) 191 (675 to 314) .42
Outpatient visits 573 (2690) 517 (1709) 56 (200 to 415) .71
Other care 257 (1106) 346 (1377) 89 (270 to 68) .29
Total 18,348 (30,610) 16,149 (36,125) 2199 (2536 to 6435) .33
Median (IQR) 9090 (5799, 16,895) 6183 (3163, 13,718)
Total at 1 year 60,053 (47,422) 63,252 (82, 513) 3199 (12,939 to 5054) .48
Median (IQR) 47,705 (37,315, 64,809) 43,633 (30,782, 65,479)
AAA repair, 1 to 2 years 0 (0) 632 (10,147) 632 (3327 to 104) .005
1 to 2 years, other
VA costs
Acute inpatient care 3978 (15,108) 5465 (19,693) 1487 (4018 to 674) .21
Rehabilitation, mental health, and
long-term care 402 (6419) 841 (6942) 438 (1259 to 559) .33
Outpatient visits 5689 (8582) 5048 (7227) 641 (344 to 1718) .23
Outpatient pharmacy 1176 (1818) 1250 (2184) 75 (369 to 172) .58
Non-VA costs
Acute inpatient care 2312 (11,668) 2660 (14,848) 347 (2407 to 1122) .70
Nursing home 543 (4427) 210 (1924) 333 (5 to 981) .15
Outpatient visits 961 (5991) 645 (2431) 316 (128 to 1130) .30
Other care 211 (938) 341 (1941) 130 (390 to 22) .21Total, 1 year to 2 year 15,272 (28,255) 17,091 (38,426) 1820 (6105 to 2425) .42
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($23,153 vs $18,586).3 Likewise, in the Dutch Random-
ized Endovascular Aneurysm Management (DREAM)
trial, endovascular repair cost significantly more than open
repair after 1 year (€18,179 vs €13,886).7 A nonrandom-
ized study based on a 20% sample of U.S. hospital admis-
sions in 2001 also found endovascular repair to be associ-
ated with higher hospital charges than open repair
($50,346 vs $47,009).24
There are several possible explanations for the differ-
ence between our findings and those of the earlier reports.
First, we studied more recent procedures, having entered
patients between 2002 and 2007, compared with 1999 to
2003 for EVAR-1 and DREAM and 2001 for the U.S.
sample. Expenses per inpatient day increased by 50% in
the U.S. from 1999 to 2007,25 whereas the cost of endo-
vascular grafts changed little during this period.
Second, open repair could have fared relatively worse in
our study than in the European trials because the cost of a
day in the hospital is substantially higher in the U.S. than in
Europe, whereas the costs of endovascular grafts are more
similar.3,7
Third, the VA cost-accounting methods used in our
study, which include fixed direct and indirect costs, may
capture costs of hospitalization more thoroughly than did the
previous studies, again, causing open repair to fare worse.
Results similar to ours were obtained in a Swedish
population-based study of 109 patients who underwent AAA
repair in 2001 to 2005.26 After a mean of 2.5 years, there was
a nonsignificant trend toward lower AAA-associated costs
with endovascular repair (€26,382) than with open repair
(€29,786). This study was not randomized, however, and
there were significant differences between the two groups
at baseline. A Canadian study found nearly identical costs at
1 year between the two procedures in 192 high-risk pa-
Table III. Continued.
Variablea
Endovascular repair
(n  444)
Median (IQR) 6511 (2772, 16,322)
Total at 2 years 75,325 (58,879)
Median (IQR) 59,782 (43,666, 82,568
AAA, Abdominal aortic aneurysm; CI, confidence interval; IQR, interquart
aCosts are in U.S. dollars and are shown as means (standard deviations) exc
Table IV. Quality of life from randomization to 2 years
as measured by EuroQol-5D (EQ-5D) scores
EQ-5D scoresa
Endovascular repair
(n  444)
Open repair
(n  437) P
Baseline 0.785 (0.176) 0.789 (0.173) .76
6 months 0.756 (0.217) 0.757 (0.231) .93
1 year 0.735 (0.242) 0.742 (0.252) .68
2 years 0.715 (0.262) 0.700 (0.286) .42
aValues are mean (standard deviation).tients undergoing repair from 2003 to 2005.27 A literature- aased model developed for the U.K. National Institute for
ealth and Clinical Excellence in 2009 concluded that
ndovascular repair was likely to bemore cost-effective than
pen repair in higher-risk patients.28
Our study has several limitations: First, some costs
hat might seem to apply to only one group are distrib-
ted as fixed direct costs among all patients in both
roups, such as disposable supplies (eg, guidewires,
heaths, sutures, cell-saving devices, balloons) and items
ought for repeated use (eg, to equip an operating room
r endovascular suite).
Second, the cost of some preoperative evaluations was
ot included because patients had to be candidates for both
rocedures before randomization. In some patients, this
ight have required more imaging than would otherwise
ave been used before open repair.
Third, although our study was intended to closely repli-
ate usual practice inmost respects, there were a few protocol-
riven deviations that could distort costs, such as the required
omputed tomography scan 1 year after open repair.
Fourth, we did not collect QOL data between base-
ine and 6 months, a period during which some studies29
ave observed a transient difference favoring endovascu-
ar repair.
Fifth, our study was conducted at VA medical centers
nd used VA accounting methods and so our results may
ot directly apply to other populations (ie, women, of
hom there were only 5 in our study) in other health care
ettings. However, our population is otherwise typical of
atients with AAA, who are predominantly older men with
history of smoking. Furthermore, the VA is the largest
ntegrated health care system in the U.S., providing care
o 6 million veterans,30 to whom our results are directly
pplicable. The accounting methods we used have been
eveloped over more than a decade by economists at the
A Health Economics Resource Center, have been used in
umerous federally funded economic studies, and may
erve as a model for cost-accounting in other systems.
lthough it has been alleged at times that VA costs for care
ight be higher than costs for care obtained in non-VA
ealth care,31 the best evidence indicates that this is not the
ase.32 The VA may be obtaining some items, such as
edications and, in our study, endovascular grafts, at lower
osts than non-VA users. In settings in which endovascular
rafts costs are substantially different from the mean
14,052 per patient we observed, our findings may not
Open repair
(n  437) Cost difference (95% CI) P
5810 (2356, 16,002)
0,344 (96,436) 5019 (16,720 to 4928) .35
5,153 (38,262, 85,369)
ge; VA, Department of Veterans Affairs.
en median (IQR) is specified. See the Methods section for explanation.8
) 5
ile ranpply.
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October 2012908 Stroupe et alFinally, we reported all health care costs rather than
only those related to AAA repair, which some might con-
sider a limitation. In fact, assessment of all costs is the
preferred method recommended by guidelines.19 The
trade-off is between dilution of the effect of the interven-
tion when all costs are used vs errors introduced in attempt-
Fig. Cost-effectiveness planes. Bootstrap replications sh
quality-adjusted life-years (QALYs) on the cost-effective
open repair at 2 years of follow-up. The large dot indicating to identify intervention-related costs. Because this anal- tsis was limited to 2 years and most of the costs were clearly
ntervention-related, dilution could be expected to be min-
mal, favoring our selection of all costs.
ONCLUSIONS
Endovascular repair represents an important advance in
e differences in costs and (A) life-years (LYs) and (B)
plane between patients randomized to endovascular or
e point estimate from the study.ow thhe treatment of AAA.Our findings show that endovascular
11
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JOURNAL OF VASCULAR SURGERY
Volume 56, Number 4 Stroupe et al 909repair is a cost-effective alternative to open repair in the
U.S. VA health care system, at least in the first 2 years.
Because some studies have found endovascular repair re-
quires more late reinterventions than open repair, which
could adversely affect long-term cost-effectiveness, it will
be important to re-examine cost-effectiveness again at the
end of our 9-year study.
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Albuquerque, NM VAMC: Erika R. Ketteler MD,
Darra D. Kingsley, MD, John M. Marek, MD, Richard J.
Massen, MD, Brian D. Matteson, MD, J. David Pitcher,
MD, Mark Langsfeld, MD, John D. Corson, MD, James
M. Goff, Jr, MD, Karthnik Kasirajan, MD, Christina Paap,
RN, Diane C. Robertson, RN
Atlanta, Ga VAMC: Atef Salam, MD, Ravi Veeras-
wamy, MD, Ross Milner, MD, Karthikeshwar Kasirajan,
MD, Jane Guidot, RN
Baltimore, Md VAMC: Brajesh K. Lal, MD, Steven J.
Busuttil, MD, Michael P. Lilly, MD, Melita Braganza, Kea
Ellis, RN
Birmingham, Ala VAMC: Mark A. Patterson, MD,
WilliamD. Jordan, MD, DavidWhitley, MD, Steve Taylor,
MD, Marc Passman, MD, Donna Kerns, RN, Cindy In-
man, RN, Jennifer Poirier, RN
Boston, Mass VAMC: James Ebaugh, MD, Joseph
Raffetto, MD, David Chew, MD, Subhash Lathi, MD,
Christopher Owens, MD, Kathleen Hickson, RN
Buffalo, NY VAMC: Hasan H. Dosluoglu, MD,
Karen Eschberger, RN
Chicago, Ill VAMC: Melina R. Kibbe, MD,HenryM.
Baraniewski, MD, Jon Matsumura, MD, Michelle Endo,
Anna Busman, RN, Wendy Meadows, RN, Mary Evans,
RN
Cincinnati, Ohio VAMC: Joseph S. Giglia, MD, Ho-
sam El Sayed, MD, Amy B. Reed, MD, Madeline Ruf, RN,
Stephanie Ross, RN
Cleveland, Ohio VAMC: Jessie M. Jean-Claude, MD,
Gilles Pinault, MD, Preet Kang, MD, Nadine White, RN,
Matthew Eiseman, RN, Reba Jones, RN†
Dallas, Tex VAMC: Carlos H. Timaran, MD, J. Greg-
ory Modrall, MD, M. Burress Welborn III, MD, Jorge
Lopez, MD, Tammy Nguyen, MT (ASCP)
Detroit, Mich VAMC: John K.Y. Chacko, MD, Ken-
nethGranke,MD, Angela G. Vouyouka,MD, ErinOlgren,
Prakash Chand, MD, Brenda Allende, Michael Ranella,
Claudia Yales, RN
Denver, Colo VAMC: Thomas A. Whitehill, MD,
William C. Krupski, MD†, Mark R. Nehler, MD, Stephen
P. Johnson, MD, Darrell N. Jones, PhD, Pamela Strecker,
RN, Michelle A. Bhola, RN
Durham, NC VAMC: Cynthia K. Shortell, MD, John
L. Gray, MD, Jeffrey H. Lawson, MD, Richard McCann,
MD, Mark W. Sebastian, MD, Jean Kistler Tetterton, NP,
Carla Blackwell, RN, Patricia A. Prinzo, BS, Nina Lee, RN
East Orange, NJ VAMC: Frank T. Padberg, Jr, MD,
Joaquim J. Cerveira, MD, Brajesh K. Lal, MD, Robert W.
Zickler, MD, Karen A. Hauck, RN
Gainesville, Fla VAMC: Scott A. Berceli, MD, W.
Anthony Lee, MD, C. Keith Ozaki, MD, Peter R. Nelson,
MD, Anne S. Irwin, RN, Randy Baum, RN MHines, Ill VAMC: Bernadette Aulivola, MD, Heron
odriguez, MD, Fred N. Littooy, MD, Howard Greisler,
D, Mary T. O’Sullivan, RN
Houston, Tex VAMC: Panagiotis Kougias, MD, Pe-
er H. Lin, MD, Ruth L. Bush, MD, Gene Guinn, MD,
arlos Bechara, MD, Catherine Cagiannos, MD, Sherilyn
illack, RN, Barbara Guillory, RN
Indianapolis, Ind VAMC: Dolores Cikrit, MD, Ste-
hen G. Lalka, MD, Gary Lemmon, MD, Ryan Nach-
einer, MD, Mitzi Rusomaroff, RN, Elaine O’Brien, RN
Iowa City, Iowa VAMC: Joseph J. Cullen, MD, Jamal
oballah, MD, W. John Sharp, MD, Jeanne L. McCandless,
N, Vickie Beach, RN
Lexington, Ky VAMC: David Minion, MD, Thomas
. Schwarcz, MD, Joy Kimbrough, RN, Laura Ashe, Anna
ockich, MS, Jill Warner-Carpenter, RN
Little Rock, Ark VAMC: Mohammed Moursi, MD,
ohn F. Eidt, MD, Sandra Brock RN
Loma Linda, Calif VAMC: Christian Bianchi, MD,
icki Bishop, RN
Long Beach, Calif VAMC: Ian L. Gordon, MD, Roy
ujitani, MD, Stephen M. Kubaska, III, MD, Mina Beh-
ad, MD, Reza Azadegan, MD, Christine Ma Agas, MPH,
athy Zalecki
Madison, Wisc VAMC: John R. Hoch, MD, Sandra
. Carr, MD, Charles Acher, MD, Margaret Schwarze,
D, Girma Tefera, MD, Matthew Mell, MD, Beth Dun-
ap, RN, Janice Rieder, RN
Memphis, Tenn VAMC: John M. Stuart, MD, Darryl
. Weiman, MD, Omran Abul-Khoudoud, MD, H. Ed-
ard Garrett, MD, Sandra M. Walsh, MA, Karen L. Wil-
on, RN
Milwaukee, Wisc, VAMC: Gary R. Seabrook, MD,
obert A. Cambria, MD, Kellie R. Brown, MD, Brian D.
ewis, MD, Susan Framberg, RN, Christa Kallio, RN
Minneapolis, Minn VAMC: Roderick A. Barke, MD,
teven M. Santilli, MD, Alexandre C. d’Audiffret, MD,
ancy Oberle, RN, Catherine Proebstle, NP, Lauri Lee
ohnson, RN
New York, NY VAMC: Glenn R. Jacobowitz, MD,
eal Cayne, MD, Caron Rockman, MD, Mark Adelman,
D, Paul Gagne, MD, Matthew Nalbandian, MD, Leah
. Caropolo, BS
Omaha, Neb VAMC: Iraklis I. Pipinos, MD, Jason
ohanning, MD, Thomas Lynch, MD, Holly DeSpiegelaere,
N, Georgia Purviance, RN
Palo Alto, Calif VAMC: Wei Zhou, MD, Ronald
alman, MD, Jason T. Lee, MD, Bassem Safadi, MD,
heila M. Coogan, MD, Sherry M. Wren, MD, Doghdoo
. Bahmani, Deanna Maples, NP, Shawna Thunen, RN
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arc E. Mitchell, MD, Ronald Fairman, MD, Sally Rein-
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